Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Network brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:




    Connect with us

    Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

    Pharmaceutical sector news

    Life Science Alert

     

    EY-Applying IFRS 10 and IFRS 11

    Applying IFRS 10 and IFRS 11

    How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.